Alector (ALEC) vs Protalix BioTherapeutics (DE) (PLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Protalix BioTherapeutics (DE) (PLX) has outperformed Alector (ALEC) over the past year, gaining 8.4% versus a loss of 37.5%. Over five years, PLX leads with a +120.3% price change compared with -91.8% for ALEC. Protalix BioTherapeutics (DE) is the larger company by market cap ($218.3 million vs $214.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | PLX |
|---|---|---|
| Share price | $1.92 | $2.71 |
| Market cap | $214.38M | $218.35M |
| 1-day change | +6.08% | -0.73% |
| YTD return | +23.08% | +50.56% |
| 1-year return | -37.46% | +8.40% |
| 5-year return | -91.76% | +120.33% |
| P/E ratio (TTM) | — | 11.78 |
| Forward P/E | — | 4.37 |
| EPS (TTM) | $-1.09 | $0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.40 | $3.19 |
| 52-week low | $1.09 | $1.60 |
| Distance from 52-week high | -43.53% | -15.05% |
| Analyst consensus | hold | none |
| Avg. price target upside | +71.88% | +305.90% |
| Average volume | 2.77M | 732.64K |
| Shares outstanding | 111.66M | 80.57M |
| Employees | 103 | 226 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLX has outperformed ALEC by 45.9 percentage points over the past year.
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees
About Protalix BioTherapeutics (DE)
PLX stock →Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees
ALEC vs PLX FAQ
Which is bigger, Alector or Protalix BioTherapeutics (DE)?
Protalix BioTherapeutics (DE) (PLX) is larger, with a market capitalization of $218.35M compared with $214.38M for Alector (ALEC).
Which stock has performed better over the past year, ALEC or PLX?
PLX returned +8.40% over the past 12 months, compared with -37.46% for ALEC (price return, excluding dividends). Past performance does not predict future results.
Are Alector and Protalix BioTherapeutics (DE) in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.